RankingsPricing
  1. US-listed companies
  2. Intra-Cellular Therapies, Inc.
  3. Financials
  4. Net income margin (%)

Intra-Cellular Therapies, Inc.ITCI

Market cap
$13.4B
P/E ratio
SummaryFinancials
Period EndNet income margin (%) YoY (%)
Dec 31, 2024-11-63.53%
Dec 31, 2023-30.1-70.62%
Dec 31, 2022-102.4-69.80%
Dec 31, 2021-339-65.93%
Dec 31, 2020-995.1-99.59%
Dec 31, 2019-243,713.7+512.78%
Dec 31, 2017-39,771.6+12.97%
Dec 31, 2016-35,205.8-69.31%
Dec 31, 2015-114,698.5+2057.46%
Dec 31, 2014-5,316.4+441.57%
Dec 31, 2013-981.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)